Navigation Links
Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
Date:4/3/2008

BALTIMORE, April 3, 2008 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Bruce A. Peacock as its Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Peacock is a Venture Partner with SV Life Sciences Advisors, LLC. Previously, he served as the CEO or was a member of the senior management team for several successful entrepreneurial healthcare companies operating in therapeutic, diagnostic and service areas including The Little Clinic, Adolor Corporation, Orthovita, Inc., Cephalon, Inc., and Centocor, Inc.

"Mr. Peacock brings a wealth of experience and leadership with a proven track record of success," said Dan Janney of Alba's Board of Directors. "His experience in leading successful research and development and commercial infrastructures will be invaluable to Alba."

In a related announcement, Blake M. Paterson, MD, Alba's CEO and Co- Founder since its inception in 2004, has left the company to pursue other advisory and entrepreneurial interests. Since founding the Company, Dr. Paterson has raised over $40 million in funding for the Company and under his direction and leadership Alba has grown into a thriving Baltimore biotechnology company with 45 employees in its headquarters at the University of Maryland BioPark. This growth has led to the achievement of significant milestones including successful proof-of-concept for Alba's clinical candidate, larazotide acetate in celiac disease and the establishment of a licensing and collaboration agreement worth up to $325 million with Shire Pharmaceuticals.

"The addition of Mr. Peacock to the Alba management team will position the Company for the next level of financial and developmental success. I look forward to continuing to support the Alba team in their endeavors, as founder and past president," said Dr. Blake Paterson.

Dr. Lutz Giebel of Alba's Board of Directors commented, "We are extremely grateful to Blake for his commitment, dedication, vision and passion for the broad technology platform Alba has created and for helping to create medicines for patients with unmet medical needs. We will continue to count on his valuable perspective as the Company moves forward."

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Contact: Wendy Perrow, MBA

Phone: 410-878-9850

E-mail: info@albatherapeutics.com

Web site: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... York, NY (PRWEB) , ... October 12, 2017 ... ... Academy of Sciences today announced the three Winners and six Finalists of the ... are given annually by the Blavatnik Family Foundation and administered by the New ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
Breaking Biology News(10 mins):